ICON Public Limited Company research snapshot
ICLR AI stock analysis currently reads ICON plc as a large global clinical research organization with improving commercial momentum, a $22.7 billion backlog, and free cash flow that still funds the balance sheet, but near-term profitability and trust in reported numbers remain the main constraints. At the July 12, 2026 data cutoff, ICLR last closed near $167.72 with a verified market capitalization of about $12.85 billion using 76.60 million shares. FY2025 revenue was $8.251 billion, while GAAP net income fell to $229.3 million and adjusted diluted EPS was $12.53. Q1 2026 delivered $2.034 billion of revenue, a 1.42x net book-to-bill, and reaffirmed 2026 revenue guidance of $7.85 to $8.15 billion with adjusted diluted EPS of $10.00 to $11.00. This page uses scenarios, technical levels, and source-backed facts. It is informational research, not investment advice.
Current price
$167.72
Market cap
$12.85 billion
AI score
64 / 100
Rating
Scaled global CRO with strong bookings but margin pressure, GAAP noise, and remediation overhang
Trend status
Short-term bounce above the 50-day and 200-day moving averages after a deep drawdown, with RSI near 70
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | ICON sells outsourced clinical development, laboratory, consulting, and related services to pharmaceutical, biotech, and medical device sponsors. Customers pay for trial execution capacity, regulatory know-how, and global delivery rather than a pure product. | High |
| Moat | The moat comes from global trial scale after the PRA Health Sciences combination, multi-year sponsor relationships, laboratory and functional service breadth, and a reported backlog of $22.7 billion at March 31, 2026. It is not an impenetrable brand moat and can erode with cancellations or pricing pressure. | Medium-high |
| Management | Barry Balfe became CEO on October 1, 2025 after long-time CEO Dr. Steve Cutler retired. Capital allocation has included sizable buybacks, while the board has been refreshed following the accounting investigation. Execution and control remediation are the central tests. | Medium |
| Financial trend | FY2025 revenue rose 0.8% to $8.251 billion, but GAAP net income fell to $229.3 million and free cash flow was $862.0 million. Q1 2026 revenue was $2.034 billion with adjusted EBITDA margin of 15.6% and adjusted diluted EPS of $2.50, below year-earlier adjusted levels. | High |
| Valuation | At $167.72, ICLR traded near 1.38x book value, about 1.56x FY2025 sales, about 14.9x FY2025 free cash flow per share, and about 16.0x the midpoint of 2026 adjusted EPS guidance. Trailing GAAP PE is distorted by impairments and one-time items. | High |
| Technical trend | After a deep 2026 drawdown and late-June bounce, price sat above the roughly $139.66 50-day and $149.07 200-day moving averages, while RSI near 70.29 showed strong but extended short-term momentum. | Medium |
| Risk level | Key risks are accounting and control remediation, margin compression, trial cancellations, biotech funding swings, large-sponsor concentration, CEO transition, competition, and multiple compression if bookings or guidance slip. | Medium-high |
| AI confidence | High for descriptive research and audited market-cap and scenario math. Lower for exact return outcomes because small changes in book-to-bill, cancellations, or PE multiple can move the equity materially. | High data confidence |
| Investment certainty | Medium-low certainty at current prices. The commercial pipeline looks better, but earnings quality, margin recovery, and remediation progress still need confirmation before high-conviction compounding claims are justified. | Medium-low |
ICLR AI stock forecast
The ICLR AI stock forecast uses scenario math around the $167.72 quote and the midpoint of management 2026 adjusted diluted EPS guidance near $10.50. The audited three-year framework produced a bearish area near $98 to $110, a base area near $165 to $200, and a bullish area near $250 to $290 before any future buyback effect. The range is wide because ICON combines a sticky CRO backlog with margin, accounting, and multiple uncertainty.
$250 to $290
More likely if adjusted EPS compounds near 8% to 10% annually from the 2026 guidance base, net book-to-bill stays above 1.2x, cancellations remain moderate, adjusted EBITDA margin rebuilds toward the high teens, free cash flow funds debt reduction and buybacks, remediation closes cleanly, and the market values ICLR near 18x to 20x earnings.
$165 to $200
More likely if 2026 revenue lands inside $7.85 to $8.15 billion, adjusted diluted EPS lands near $10 to $11, backlog conversion is orderly, net leverage stays near 1.8x, margins stabilize rather than fully re-expand, and ICLR trades around 15x to 16x adjusted earnings.
$90 to $110
More likely if cancellations rise, biotech and large-pharma budgets weaken, backlog burn slows, accounting or control issues reappear, adjusted EPS misses the guided range, and the market compresses ICLR toward 11x to 12x depressed earnings.
ICLR AI technical analysis
ICLR AI technical analysis is constructive on the bounce but still recovery-shaped as of the July 12, 2026 cutoff. Price reclaimed both the 50-day and 200-day moving averages after a large drawdown, while RSI near 70 suggests short-term momentum is extended. Technical levels should be refreshed with live chart data before trading.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $167.72 | July 10, 2026 close used for market cap and valuation math at the July 12 data cutoff. |
| Near support | $149 to $155 | The 200-day moving average near $149.07 and the mid-$150 zone form the first support band if the post-earnings bounce cools. |
| Deeper support | $135 to $140 | The 50-day moving average near $139.66 and the late-June pre-spike area are the deeper trend references if the rally fails. |
| Near resistance | $175 to $188 | This band covers the early-2026 supply zone and prior local highs near the high $180s before the drawdown. |
| 50-day moving average | About $139.66 | Price was well above this intermediate trend gauge after the late-June recovery, supporting a repaired short-term trend unless it fails on volume. |
| 200-day moving average | About $149.07 | Price was above this longer-term gauge, which is a practical bull-or-bear line for the repaired medium-term trend. |
| Momentum | RSI about 70.29 | Momentum was strong and near the typical overbought threshold, so chase entries need tighter invalidation rules. |
| Volume | About 1.0 million average recent daily shares | Breakouts above $175 to $188 should be judged against recent average volume because low-volume advances can fade around earnings and guidance updates. |
| Volatility | Beta about 1.22 | ICLR tends to move more than the market around earnings, booking updates, biotech funding headlines, and CRO peer moves. |
| Invalidation | Close below $149, then $140 | A close below the 200-day moving average would weaken the repaired trend. A break below the 50-day area would signal a failed bounce setup. |
ICLR AI trading strategy
The ICLR AI trading strategy is a rules-based research framework for a scaled CRO recovering from demand, margin, and accounting stress. It is not personal advice and should be paired with live quotes, filings, position sizing, and risk controls.
Watch for ICLR to hold above the 200-day moving average near $149 and build above $175 with volume confirmation, stable 2026 guidance, and no deterioration in net book-to-bill or cancellations.
A close below about $149 should invalidate the short-term trend setup, especially if it follows weak bookings, lower backlog, or fresh control-remediation concerns.
If ICLR pulls back toward the $140 to $155 support zone without a new accounting, demand, or large-sponsor shock, compare the price with 2026 adjusted EPS guidance, free cash flow, net leverage, and the three-scenario valuation range.
Do not average down without a defined loss limit because CRO multiples can re-rate quickly when cancellations rise or margin recovery disappoints.
Track net business wins, book-to-bill, cancellations, backlog burn, adjusted EBITDA margin, free cash flow conversion, net debt to adjusted EBITDA, share repurchases, remediation milestones, large-pharma RFP flow, and biotech funding conditions.
Reduce confidence if EPS depends mostly on buybacks or multiple expansion while organic revenue, margins, and control remediation weaken.
Investment research summary
ICON helps pharmaceutical, biotech, and medical device sponsors design, run, and analyze clinical trials and related development work. Customers pay because outsourcing global trial execution, site networks, labs, and functional services can be faster and more flexible than building every capability in-house.
The moat is built from global delivery scale, multi-year sponsor relationships, laboratory and functional service breadth, and a large backlog. It weakens if sponsors pull work in-house, lower-cost CROs win share, cancellations rise, or pricing power fades during budget freezes.
The thesis fails if net book-to-bill falls below replacement, cancellations spike, margin recovery never arrives, accounting or control issues re-emerge, large sponsors cut outsourcing, or the market refuses to re-rate ICON while peers like IQVIA compound more cleanly.
Barry Balfe took over as CEO on October 1, 2025 after Steve Cutler retired, and Cutler later left the board in May 2026. The key capital allocation questions are whether buybacks create value while net debt remains around $2.6 billion and whether remediation restores reporting credibility.
Drug development complexity, specialty and oncology pipelines, decentralized trial tools, and sponsor preference for flexible outsourcing support long-term CRO demand. The counterweight is that client spending can pause when biotech funding tightens or large pharma re-prioritizes portfolios.
ICLR is priced more like a recovery CRO than a pristine compounder. Margin of safety depends on free cash flow durability, guidance delivery, backlog conversion, leverage discipline, and clean remediation. Trailing GAAP multiples are not useful without adjustment for impairments and one-time noise.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| ICLR price | $167.72 close on July 10, 2026 | Yahoo Finance daily chart history | July 12, 2026 |
| Market capitalization | $12.85 billion, verified as $167.72 x 76.601538 million shares with 0.00% variance | financial_rigor.py market cap verification | July 12, 2026 |
| Shares outstanding | 76.60 million shares at March 31, 2026 (company report); some market vendors show about 77.15 million for a $12.94 billion market cap | ICON Q1 2026 Form 6-K and StockAnalysis statistics | July 12, 2026 |
| FY2025 revenue | $8.251 billion, cross-validated against ICON FY2025 release and Macrotrends with 0.00% variance | ICON FY2025 results release and Macrotrends | July 12, 2026 |
| FY2025 GAAP net income and adjusted EPS | $229.3 million GAAP net income, $2.90 GAAP diluted EPS, $989.8 million adjusted net income, and $12.53 adjusted diluted EPS | ICON FY2025 results release | July 12, 2026 |
| Q1 2026 operating results | $2.034 billion revenue, $104.8 million GAAP net income, $1.36 GAAP diluted EPS, $317.7 million adjusted EBITDA, 15.6% adjusted EBITDA margin, and $2.50 adjusted diluted EPS | ICON Q1 2026 results release | July 12, 2026 |
| Backlog and bookings | $22.7 billion closing backlog at March 31, 2026, $2.880 billion net business wins in Q1 2026, and 1.42x net book-to-bill | ICON Q1 2026 results release and investor deck | July 12, 2026 |
| Cash, debt, and net debt | $765.2 million cash, $3.3965 billion total debt, and $2.6313 billion net debt at March 31, 2026, with net debt to TTM adjusted EBITDA of 1.8x | ICON Q1 2026 investor presentation | July 12, 2026 |
| Free cash flow | $862.0 million free cash flow in FY2025 and $758.9 million TTM free cash flow at March 31, 2026; Q1 2026 free cash flow was $136.2 million | ICON FY2025 release and Q1 2026 investor presentation | July 12, 2026 |
| 2026 guidance | Revenue $7.85 to $8.15 billion and adjusted diluted EPS $10.00 to $11.00, reaffirmed with Q1 2026 results | ICON Q1 2026 results release | July 12, 2026 |
| Valuation ratios | About 1.38x PB, 1.56x FY2025 sales, 14.9x FY2025 FCF per share, and about 16.0x midpoint 2026 adjusted EPS; trailing GAAP PE is distorted by low GAAP earnings | StockAnalysis statistics and financial_rigor.py valuation verification | July 12, 2026 |
| Technical snapshot | 50-day moving average about $139.66, 200-day moving average about $149.07, RSI about 70.29, beta about 1.22, and recent average volume near 1.0 million shares | Yahoo Finance daily chart history and market summaries | July 12, 2026 |
| CEO transition | Barry Balfe became CEO effective October 1, 2025 after Dr. Steve Cutler retired; Cutler later resigned from the board effective May 21, 2026 | ICON CEO transition release and leadership page | July 12, 2026 |
| Accounting investigation outcome | ICON reported that the Audit Committee investigation into certain accounting practices was complete with FY2025 results, while remediation of material weaknesses remains a disclosed risk | ICON FY2025 results release and Q1 2026 presentation caution language | July 12, 2026 |
This ICLR AI stock analysis page is an informational tool only and is not investment advice, financial advice, or a recommendation to buy or sell any security. Forecast ranges are scenarios based on available public data as of July 12, 2026 and may be wrong. Always verify live market data, company filings, and your own risk constraints before making investment decisions.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
